Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European report gets nasty about NICE and the QALY

This article was originally published in Scrip

Executive Summary

The QALY-based approach used by NICE, the health technology appraisal institute for England and Wales, is heavily flawed and should not be adopted by other European member states, warns a European Commission-sponsored project. The four main assumptions underpinning the QALY about how patients value additional life gain and different health states are invalid, according to the survey. "Everything it is based upon is wrong," said Ariel Beresniak, leader of the project which reported its results at a symposium in Brussels on 25 January.

You may also be interested in...



EU Pharmaceutical Strategy Roadmap Seen As Weak On Innovation

Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.

Australia’s TGA Seeks Feedback on Data Matrix Code Labeling

The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.

EMA Scientific Advice Demand Up But Not For Orphan Drugs

The European Medicines Agency received more requests for scientific advice in 2019 than it did in 2018. Meanwhile, requests for advice in other areas has fallen.

Topics

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel